ReviewNeuroscience and biobehavioral reviews2018
Treatment resistant depression: A multi-scale, systems biology approach.
Review in Neuroscience and biobehavioral reviews, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 218 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
218 citing papers in PubMed, 6 syntheses or guidelines pooled it.
- Gene expression signatures of response to fluoxetine treatment: systematic review and meta-analyses.Molecular psychiatry · 2025Pooled it
- miRNAs in treatment-resistant depression: a systematic review.Molecular biology reports · 2024Pooled it
- Pooled it
- Pharmacokinetic Markers of Clinical Outcomes in Severe Mental Illness: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Economic evaluation of interventions for treatment-resistant depression: A systematic review.Frontiers in psychiatry · 2023Pooled it
- Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.Psychopharmacology · 2021Pooled it
- Functional connectivity subtypes during a positive mood induction: Predicting clinical response in a randomized controlled trial of ketamine for treatment-resistant depression.Journal of psychopathology and clinical science · 2025Trial
- Preliminary evidence that ketamine alters anterior cingulate resting-state functional connectivity in depressed individuals.Translational psychiatry · 2023Trial
- Pursuing personalized medicine for depression by targeting the lateral or medial prefrontal cortex with Deep TMS.JCI insight · 2023Trial
- Montgomery-Åsberg Depression Rating Scale factors in treatment-resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine.International journal of methods in psychiatric research · 2022Trial
- A pilot investigation of accelerated deep transcranial magnetic stimulation protocols in treatment-resistant depression.European archives of psychiatry and clinical neuroscience · 2021Trial
- Metabolic activity in subcallosal cingulate predicts response to deep brain stimulation for depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Assessment of Relationship of Ketamine Dose With Magnetic Resonance Spectroscopy of Glx and GABA Responses in Adults With Major Depression: A Randomized Clinical Trial.JAMA network open · 2020Trial
- Ketamine metabolite pilot study in a suicidal depression trial.Journal of psychiatric research · 2019Trial
- SCTR-Expressing Astrocyte-Serotonergic Neuron Signaling Drives Sexual Dimorphism in Depression Through KAT7/H4ac-Foxc2 Epigenetic Axis in an AMPK-Dependent Manner.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Regular intake of caffeinated but not decaffeinated coffee attenuates behavioral modifications in mice subject to chronic unpredictable stress.Neurobiology of stress · 2026Article
- The association between high-sensitivity C-reactive protein and depression symptom severity among U.S. adults: A multivariable analysis of NHANES data.Brain, behavior, & immunity - health · 2026Article
- Transcriptional profiles of antidepressant resistance across the corticolimbic pathway of chronically stressed mice.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Article
- Towards Mechanism-Informed Treatments for Mental Health.Journal of neurochemistry · 2026Review
- PARP Inhibition with 3-Aminobenzimide Attenuates Behavioral, Cardiovascular, and Neuroinflammatory Effects of Chronic Stress.bioRxiv : the preprint server for biology · 2026Article
158 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
An estimated 50% of depressed patients are inadequately treated by available interventions. Even with an eventual recovery, many patients require a trial and error approach, as there are no reliable guidelines to match patients to optimal treatments and many patients develop treatment resistance over time. This situation derives from the heterogeneity of depression and the lack of biomarkers for stratification by distinct depression subtypes. There is thus a dire need for novel therapies. To address these known challenges, we propose a multi-scale framework for fundamental research on depression, aimed at identifying the brain circuits that are dysfunctional in several animal models of depression as well the changes in gene expression that are associated with these models. When combined with human genetic and imaging studies, our preclinical studies are starting to identify candidate circuits and molecules that are altered both in models of disease and in patient populations. Targeting these circuits and mechanisms can lead to novel generations of antidepressants tailored to specific patient populations with distinctive types of molecular and circuit dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.